X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Robert Zirkelbach

Robert Zirkelbach Robert Zirkelbach is Executive Vice President of Public Affairs at PhRMA. He joins PhRMA in 2014 after working for seven years representing the health insurance industry. He likes Saturday afternoon BBQs on his deck, traveling, trying new restaurants, and attempting to play golf. He’s an avid, somewhat obsessive, Iowa Hawkeye fan and is lucky to have a wife that loves watching college football on Saturday afternoons.

Recent Posts

6 things to know before the HHS forum

By Robert Zirkelbach  |    November 19, 2015
Tomorrow, the Department of Health and Human Services (HHS) will host a forum on pharmaceutical innovation, access, affordability and better health. We welcome the opportunity to discuss how we...   Read More

What makes Valeant different than innovative biopharmaceutical companies?

By Robert Zirkelbach  |    October 22, 2015
Much like Turing, Valeant Pharmaceutical’s strategy is more reflective of a hedge fund than an innovative biopharmaceutical company. Valeant’s CEO has stated that the company’s “strategy is quite...   Read More

New poll finds majority of voters oppose government price-setting for prescription drugs

By Robert Zirkelbach  |    September 23, 2015
Majority of voters (51 percent compared to 36 percent) oppose allowing the federal government to set the price of prescription medicines, a poll released today found. The Morning Consult poll of...   Read More

3 Points You Need to Know about the Federal Government’s Health Spending Projections

By Robert Zirkelbach  |    July 28, 2015
New National Health Expenditure (NHE) projections released today by the Centers for Medicare & Medicaid Services (CMS) call into question claims that have been made in recent months about the...   Read More

Focusing on Only 1% of Spending Will Not Solve Nation’s Health Care Challenges

By Robert Zirkelbach  |    July 23, 2015
Commentary published today in Mayo Clinic Proceedings highlights a critical challenge facing cancer patients: the ability to access the medicines they need. But rather than address this issue...   Read More

Are new hep C treatments cost effective? Doctors say answer is “a resounding yes”

By Robert Zirkelbach  |    July 14, 2015
In case you missed it, a recent Bloomberg story features a new report from an influential panel of doctors and medical experts which finds that new treatments for hepatitis C are “cost effective.”...   Read More

WSJ Editorial: SCOTUS Needs to Hear Alameda Case

By Robert Zirkelbach  |    May 18, 2015
A new editorial in the Wall Street Journal, “Bad Drug Trip in Alameda,” highlights a case currently before the Supreme Court (SCOTUS), PhRMA v. Alameda, that challenges a drug take-back program...   Read More

Yet Another Misleading Report on Medicine Prices

By Robert Zirkelbach  |    May 13, 2015
Today Express Scripts released yet another misleading report to promote a false narrative about medicine spending in the United States.  For more than 50 years, spending on medicines has...   Read More

Voters Agree: Congress Should Protect Patents

By Robert Zirkelbach  |    May 12, 2015
A recent poll by the Morning Consult confirms what is likely intuitive to most: strong intellectual property (IP) rights are important to voters for a variety of reasons. In the recent poll, a...   Read More

What They Are Saying: Close Patent Loopholes That Threaten Innovation for Patients

By Robert Zirkelbach  |    April 29, 2015
“When we developed these proceedings, we never thought people would use them this way” -  Former general counsel of the PTO New administrative proceedings at the Patent and Trademark Office...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates